Stock Scorecard



Stock Summary for Editas Medicine Inc (EDIT) - $7.44 as of 3/28/2024 11:18:43 AM EST

Total Score

12 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for EDIT

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for EDIT

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for EDIT

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for EDIT

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for EDIT

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update 3/20/2024 8:05:00 PM
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire 3/18/2024 9:36:00 AM
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. 3/7/2024 8:31:00 AM
1 Beaten-Down Stock With 55% Upside, According to Wall Street 3/4/2024 3:30:00 PM
Why Editas Medicine Stock Soared as Much as 42% Higher This Week 3/3/2024 2:49:00 AM
StockNews.com Upgrades Editas Medicine ( NASDAQ:EDIT ) to Hold 3/1/2024 7:16:00 AM
Editas ( EDIT ) Q4 Earnings & Revenues Top Estimates, Stock Up 2/29/2024 1:42:00 PM
Could The Recent Rally Be Buoying This Biotech Stock? 2/28/2024 5:35:00 PM
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday - Advance Auto Parts ( NYSE:AAP ) , Vipshop Holdings ( NYSE:VIPS ) , B&G Foods ( NYSE:BGS ) 2/28/2024 4:37:00 PM
Editas Medicine ( EDIT ) Reports Q4 Loss, Tops Revenue Estimates 2/28/2024 1:10:00 PM

Financial Details for EDIT

Company Overview

Ticker EDIT
Company Name Editas Medicine Inc
Country USA
Description Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 12/31/2023
Next Earnings Date 5/3/2024

Stock Price History

Last Day Price 7.44
Last Day Price Updated 3/28/2024 11:18:43 AM EST
Last Day Volume 1,281,507
Average Daily Volume 2,230,761
52-Week High 11.91
52-Week Low 6.08
Last Price to 52 Week Low 22.37%

Valuation Measures

Trailing PE N/A
Industry PE 66.35
Sector PE 60.76
5-Year Average PE -12.62
Free Cash Flow Ratio 1.88
Industry Free Cash Flow Ratio 17.10
Sector Free Cash Flow Ratio 31.04
Current Ratio Most Recent Quarter 5.39
Total Cash Per Share 3.95
Book Value Per Share Most Recent Quarter 4.38
Price to Book Ratio 1.69
Industry Price to Book Ratio 7.21
Sector Price to Book Ratio 21.66
Price to Sales Ratio Twelve Trailing Months 7.81
Industry Price to Sales Ratio Twelve Trailing Months 32.37
Sector Price to Sales Ratio Twelve Trailing Months 8.77

Share Statistics

Total Shares Outstanding 81,814,000
Market Capitalization 608,696,160
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 30.49%
Reported EPS 12 Trailing Months -2.02
Reported EPS Past Year -2.05
Reported EPS Prior Year -3.21
Net Income Twelve Trailing Months -153,219,000
Net Income Past Year -153,219,000
Net Income Prior Year -220,432,000
Quarterly Revenue Growth YOY 819.00%
5-Year Revenue Growth 19.59%

Balance Sheet

Total Cash Most Recent Quarter 323,111,000
Total Cash Past Year 323,111,000
Total Cash Prior Year 344,274,000
Net Cash Position Most Recent Quarter 323,111,000
Net Cash Position Past Year 323,111,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 349,097,000
Total Stockholder Equity Prior Year 360,680,000
Total Stockholder Equity Most Recent Quarter 349,097,000

Options

Put/Call Ratio 0.25
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.28
MACD Signal -0.10
20-Day Bollinger Lower Band 6.27
20-Day Bollinger Middle Band 9.01
20-Day Bollinger Upper Band 11.74
Beta 2.05
RSI 38.73
50-Day SMA 8.65
200-Day SMA 24.23

System

Modified 3/27/2024 11:28:32 PM EST